 2. Patients who have received one previous standard dose ara-C-containing regimen aiming at induction of complete remission CR and who have more than 5 remaining blast cells in bone marrow following the first course of remission-induction or by other means documented residual disease i.e. circulating blasts, persistent chloromas, other evident disease from day 12 on. 